Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.

Mohamed SaidHeba OmarZeinab SolimanYasmin SaadHosam DabesSozan HamedKadri ElSaeedYehia ElShazlyMagdi ElSerafy

Published in: Expert review of gastroenterology & hepatology (2018)

The use of ombitasvir, paritaprevir, and ritonavir for treatment of HCV-infected patients with advanced renal disease was safe and effective, moreover, it was associated with significantly improved eGFR.

Keyphrases

hepatitis c virus
small cell lung cancer
human immunodeficiency virus
epidermal growth factor receptor
tyrosine kinase
antiretroviral therapy
hiv infected